Anti-CD19 chimeric antigen receptor T cell therapy - Shanghai Genechem

Drug Profile

Anti-CD19 chimeric antigen receptor T cell therapy - Shanghai Genechem

Alternative Names: Anti-CD19 CAR-T cells - Shanghai Genechem

Latest Information Update: 13 May 2016

Price : $50

At a glance

  • Originator Shanghai Genechem
  • Class Antineoplastics; CAR-T cell therapies
  • Mechanism of Action CD19 antigen modulators; Cytotoxic T lymphocyte stimulants; Gene transference; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Leukaemia

Most Recent Events

  • 01 Jan 2016 Phase-I/II clinical trials in Leukaemia (Late-stage disease, Second-line therapy or greater) in China (Infusion) (NCT02672501)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top